BETTER BIOMARKERS FOR PREDICTING THE INCIDENCE OF HAVING ATHEROSCLEROSIS AND HEART ATTACKS
With
Associate Professor Christina Bursill
Co-Director, Vascular Research Centre,
South Australian Health and Medical Research Institute (SAHMRI) &
Department of Health and Medical Science,
The University of Adelaide, Australia
RESEARCHER PROFILE
Filmed in Adelaide, Australia | April 2025
Associate Professor Christina Bursill started as Co-director of the Vascular Research Centre in January 2017 at the South Australian Health and Medical Research Institute (SAHMRI) and at The University of Adelaide, Department of Health and Medical Science. She currently holds the Lin Huddleston National Heart Foundation fellowship and is a Chief Investigator on the ARC Centre of Excellence for Nanoscale Biophotonics (CNBP).
Assoc Prof Bursill is a vascular biologist with interests and expertise in vascular inflammation, atherosclerosis and angiogenesis. She completed her PhD at The University of Adelaide in lipid metabolism then headed to Oxford University for five years to undergo a postdoctoral post in the Departments of Cardiovascular Medicine and Pathology. Her postdoctoral time triggered her interest in the mechanisms that cause atherosclerosis and in particular the role of small inflammatory proteins called chemokines.
Assoc Prof Bursill returned to Australia in 2007 at the Heart Research Institute (HRI) in Sydney where she led the Immunobiology Group. In 2008, she was awarded a National Heart Foundation Career Development Fellowship. At the HRI A/Prof Bursill developed an interest in high-density lipoproteins (HDL) and through NHMRC and National Heart Foundation funding, investigated novel mechanisms of their action in models of stent biocompatibility, diabetes and wound healing. She also has an interest in using viral gene transfer techniques to over-express proteins that attenuate chemokine activity to suppress atherosclerosis and inflammatory-driven diseases. A/Prof Bursill currently holds NHMRC Ideas, Heart Foundation Vanguard and Diabetes Australia Millenium grant funding.
Recently, Christina has been focusing on finding ways to reduce atherosclerotic heart disease.
Source: Supplied
https://orcid.org/0000-0002-0682-8760
-
Identification & characterisation of molecular drivers of therapeutic resistance
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
-
Novel therapy for pancreatic cancers, targeting molecular foundation
Dr Michael Lee is an experienced medical oncologist, sub-specialising in gastrointestinal cancers and neuroendocrine tumours at the Peter MacCallum Cancer Centre.
He plays a key role in molecular tumour boards at VCCC Alliance (Victorian Comprehensive Cancer Centre) and MPCCC (Monash Partners Comprehensive Cancer Consortium), ensuring the accurate and effective use of precision medicine in cancer care across the state.
-
In his father’s footsteps as a kidney transplant specialist
Since he was a young child, Dr Collins, has been interested in kidney failure and kidney transplants in particular. His father was also a kidney specialist, and he used to sit by the phone when his father, was on call and ringing people who were being offered a kidney transplant. The joy in their voices through this interaction created a lasting and profound impact on Dr Collins. This carried through his career and today he continues to seek better outcomes for Kidney patients.
